Can an old antibiotic be used to reduce stroke damage? Fascinating potential resurrection/re-purposing of an older drug. Glaxo announces its succession plan at the top: new CEO named. Merck gets a …
Pharma News 8_30
On the Oncology front... Bayer's Nexavar shows encouraging results: Bayer and Onyx Pharmaceuticals said they were stopping a late clinical liver cancer trial with Nexavar in the Asia-Pacific region …
Pharma News 8_3
A minor comeback for Novartis' Zelnorm. Avandia gets a reprieve, of sorts...to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, …
Pharma News 7_13
Merck investing even more in its cancer portfolio - a growing trend among the top pharma companies. Takeda seeking to grow its Amitiza franchise, now that Novartis' Zelnorm has been pulled from the …
Sanofi’s Acomplia / Zimulti rejected by FDA Panel
Developing story here. As soon as I saw a few weeks ago that one of the concerns was suicidal thoughts, I figured that this drug approval was doomed. No way is the FDA going to go out on a limb with …
Continue Reading about Sanofi’s Acomplia / Zimulti rejected by FDA Panel →